Brief: Jcr Pharmaceuticals And Takeda Pharmaceuticals Announce Discontinuation Of Gene Therapy Collaboration
21/12/2023 12:47
Dec 21 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T :
* JCR PHARMACEUTICALS AND TAKEDA PHARMACEUTICALS ANNOUNCE
DISCONTINUATION OF GENE THERAPY COLLABORATION
* JCR PHARMACEUTICALS CO LTD - TERMINATION EXPECTED TO HAVE
MINOR
IMPACT ON CONSOLIDATED FINANCIAL RESULTS FOR FISCAL YEAR ENDING
ON MARCH 31, 2024
* JCR PHARMACEUTICALS CO LTD: WITH TERMINATION OF AGREEMENT,
RESULTS AND PATENTS HAVE BEEN RETURNED TO JCR
Source text for Eikon: ID:nBw2k6XDPa
Further company coverage: 4552.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results